39800-28-7

Usage

Uses

Used in Oncology:
4-HYDROPEROXYIFOSFAMIDE is used as a chemotherapy agent for the treatment of various cancer types. It is particularly effective when used in combination therapies, enhancing the overall treatment efficacy and targeting a wide range of cancer cells.
Used in Cancer Research:
In the field of cancer research, 4-HYDROPEROXYIFOSFAMIDE is utilized to study its potential applications in treating different cancer types. Ongoing studies aim to explore its effectiveness, safety, and optimal dosages for various cancer treatments.
Used in Drug Development:
4-HYDROPEROXYIFOSFAMIDE plays a role in drug development as researchers work on improving its formulation and delivery methods. This includes the development of novel drug delivery systems to enhance its bioavailability, therapeutic outcomes, and patient compliance.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, 4-HYDROPEROXYIFOSFAMIDE is an important compound for the development of new cancer treatments. Its unique properties as a prodrug and its potential for combination therapies make it a valuable asset in the ongoing fight against cancer.

InChI:InChI=1/C7H15Cl2N2O4P/c8-2-4-10-16(13)11(5-3-9)7(15-12)1-6-14-16/h7,12H,1-6H2,(H,10,13)

Upstream product

• 50892-10-9 4-Hydroxyifosfamide 
• 3778-73-2 ilfosfamide 
• 39800-35-6 O-(but-3-enyl) N,N'-bis(2-chloroethyl)phosphorodiamidate 

Downstream Products

• 50892-10-9 4-Hydroxyifosfamide 
• 53459-54-4 (2-chloro-ethyl)-(6-oxo-(9ar)-tetrahydro-6λ⁵-[1,2,4]dioxazino[4,3-c][1,3,2]oxazaphosphinin-6c-yl)-amine 
• 53459-54-4 (2-chloro-ethyl)-(6-oxo-(9ar)-tetrahydro-6λ⁵-[1,2,4]dioxazino[4,3-c][1,3,2]oxazaphosphinin-6t-yl)-amine 

Relevant academic research and scientific papers

Synthesis and antitumour activity of stereoisomers of 4-hydroperoxy derivatives of ifosfamide and its bromo analogue

Racemic mixtures and laevorotatory enantiomers of cis- and trans-4-hydroperoxyifosfamide and 4-hydroperoxybromofosfamide possess high antitumour activity both in vitro and in vivo. However, no major differences in biological activity were observed among t

COMPLEXES OF 4-HYDROPEROXY IFOSFAMIDE AS ANTI-TUMOR AGENTS

The present disclosure concerns complexes of 4-hydroperoxy ifosfamide. In one embodiment the complexes can be represented by the formula (A); wherein A represents an ammonium species selected from the conjugate acid of a basic amino acid, quaternary ammonium, aliphatic ammonium, heterocyclic ammonium, aromatic ammonium, substituted and unsubstituted pyridinium, guanidinium, and amidinium, and wherein X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.

31P NMR Studies of the Kinetics of Bisalkylation by Isophosphoramide Mustard: Comparisons with Phosphoramide Mustard

31P nuclear magnetic resonance spectroscopy was used to measure the pKa (4.28 +/- 0.2) of isophosphoramide mustard (IPM) at 20 deg C and to study the kinetics and products of the decomposition of IPM at a solution pH value of ca. 7.4 and at temperatures between 20 and 47 deg C in the presence of nucleophilic trapping agents.At 37 deg C, the half-life for the first alkylation was ca. 77 min and ca. 171 min for the second alkylation; these data may be compared with those for phosphoramide mustard (Engle, T.W.; Zon, G.; Egan, W.J.Med.Chem. 1982, 25, 1347), wherein the half-lives for the first and second alkylations are approximately the same (18 min).The rate of fragmentation of aldoifosfamide to IPM and acrolein was also studied by NMR spectroscopy (pH 7.0; 37 deg C; 0.07 M phosphate); under the noted conditions, the half-life of aldoifosfamide was fouund to be ca. 60 min.